World's Best Scientists 2026 revealed!
Judy C. Boughey

Judy C. Boughey

D-Index & Metrics

Medicine

D-Index
85
Citations
25178
World Ranking
14660
National Ranking
7417

Judy C. Boughey publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Judy C. Boughey sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 750 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Judy C. Boughey D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Judy C. Boughey sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 85 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Judy C. Boughey is affiliated with the Mayo Clinic in the United States and has contributed to research primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their published work spans numerous aspects of cancer research, oncology, surgery, pathology, and radiology with a particular focus on breast cancer.

The scientist's main research domains include:

  • Cancer Research
  • Oncology
  • Surgery
  • Pathology and Forensic Medicine
  • Radiology, Nuclear Medicine and Imaging

Boughey's work largely revolves around breast cancer, including studies on breast cancer treatment, breast lesions and carcinomas, breast implant and reconstruction, cancer genomics and diagnostics, cancer treatment and pharmacology, HER2/EGFR in cancer research, and advanced breast cancer therapies.

The most frequently published venues for their research include:

  • Annals of Surgical Oncology
  • Cancer Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Breast Cancer Research and Treatment

Frequent collaborators in their research include:

  • Matthew P. Goetz
  • Tanya L. Hoskin
  • Laura J. Esserman
  • Christina Yau
  • Krishna R. Kalari

Notable recent publications by Judy C. Boughey feature contributions on the following:

  • "Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer" (2020, JAMA Oncology)
  • "Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline" (2020, Journal of Clinical Oncology)
  • "Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial" (2021, Cancer Cell)
  • "Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer" (2020, JAMA Oncology)
  • "Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial" (2020, UNC Libraries)

Best Publications

  • Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial

    Judy C. Boughey;Vera J. Suman;Elizabeth A. Mittendorf;Gretchen M. Ahrendt

  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

    Rita Nanda;Minetta C Liu;Christina Yau;Rebecca Shatsky

  • Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

    Hope S. Rugo;Olufunmilayo I. Olopade;Angela DeMichele;Christina Yau

  • Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).

    Judy C. Boughey;Karla V. Ballman;Huong T. Le-Petross;Linda M. McCall

  • Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging

    Rajini Katipamula;Amy C. Degnim;Tanya Hoskin;Judy C. Boughey

  • Adaptive Randomization of Neratinib in Early Breast Cancer

    John W Park;Minetta C Liu;Douglas Yee;Christina Yau

  • Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial

    Judy C. Boughey;Linda M. McCall;Karla V. Ballman;Elizabeth A. Mittendorf

  • Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons

    Eric R. Manahan;Henry M. Kuerer;Molly Sebastian;Kevin S. Hughes

  • Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer : recommendations from an international working group

    Elena Provenzano;Veerle Bossuyt;Giuseppe Viale;David Cameron

  • Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    Nadine M. Tung;Judy C. Boughey;Lori J. Pierce;Mark E. Robson

  • Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.

    Rita Nanda;Minetta C. Liu;Christina Yau;Smita Asare

  • Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

    V. Bossuyt;E. Provenzano;W. F. Symmans;J. C. Boughey

  • Current status of radioactive seed for localization of non palpable breast lesions.

    James W. Jakub;Richard J. Gray;Amy C. Degnim;Judy C. Boughey

  • Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

    Aman U Buzdar;Vera J Suman;Funda Meric-Bernstam;A Marilyn Leitch

  • Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

    Lajos Pusztai;Christina Yau;Denise M. Wolf;Hyo S. Han

  • Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance)

    Judy C. Boughey;Karla V. Ballman;Kelly K. Hunt;Linda M. McCall

  • The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB)

    Oluwadamilola M. Fayanju;Oluwadamilola M. Fayanju;Yi Ren;Samantha M. Thomas;Rachel A. Greenup;Rachel A. Greenup

  • Contralateral Prophylactic Mastectomy is Associated with a Survival Advantage in High-Risk Women with a Personal History of Breast Cancer

    Judy C. Boughey;Tanya L. Hoskin;Amy C. Degnim;Thomas A. Sellers

  • Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer

    Mary Jo Fackler;Zoila Lopez Bujanda;Christopher Umbricht;Wei Wen Teo

  • DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine

    Jia Yu;Bo Qin;Ann M. Moyer;Somaira Nowsheen

Frequent Co-Authors

Matthew P. Goetz
Matthew P. Goetz Mayo Clinic
Liewei Wang
Liewei Wang Mayo Clinic
Kelly K. Hunt
Kelly K. Hunt The University of Texas MD Anderson Cancer Center
Laura J. Esserman
Laura J. Esserman University of California, San Francisco
Vera J. Suman
Vera J. Suman Mayo Clinic
Christina Yau
Christina Yau University of California, San Francisco
James N. Ingle
James N. Ingle Mayo Clinic
Kathy S. Albain
Kathy S. Albain Loyola University Chicago
Donald A. Berry
Donald A. Berry The University of Texas MD Anderson Cancer Center
Claudine Isaacs
Claudine Isaacs Georgetown University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering Medicine in the USA, there are several online degrees and alternative career routes to explore. These accredited programs often offer flexibility—making them ideal for working professionals and those looking to advance or pivot in healthcare.

For nurses aiming to reach the highest level of clinical practice, easiest online dnp programs can be a practical choice, providing advanced education through accessible online platforms. Alternatively, if you prefer a quicker entry into nursing, fast track lpn programs can help you move into the workforce efficiently.

Those interested in mental health roles may consider accelerated msn psychiatric np programs, designed to fast-track your specialization as a psychiatric nurse practitioner. For students looking beyond clinical roles, a healthcare administration degree online offers a foundation in leadership and management within the healthcare sector.

Whether your interests lie in advanced practice, administration, or entering the field quickly, these online pathways provide flexible, affordable, and accelerated options for building a career in healthcare.

Best Scientists Citing Judy C. Boughey

Trending Scientists

Recently Published Articles